Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Shares Outstanding (2019 - 2025)

Lyell Immunopharma (LYEL) has disclosed Shares Outstanding for 7 consecutive years, with $21.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 44.14% to $21.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.3 million through Dec 2025, up 44.14% year-over-year, with the annual reading at $21.3 million for FY2025, 44.14% up from the prior year.
  • Shares Outstanding hit $21.3 million in Q4 2025 for Lyell Immunopharma, up from $19.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $251.9 million in Q3 2023 to a low of $12.5 million in Q4 2022.
  • Historically, Shares Outstanding has averaged $119.1 million across 5 years, with a median of $20.3 million in 2025.
  • Biggest five-year swings in Shares Outstanding: surged 1721.4% in 2021 and later tumbled 94.91% in 2024.
  • Year by year, Shares Outstanding stood at $242.7 million in 2021, then tumbled by 94.86% to $12.5 million in 2022, then increased by 1.75% to $12.7 million in 2023, then grew by 16.11% to $14.7 million in 2024, then skyrocketed by 44.14% to $21.3 million in 2025.
  • Business Quant data shows Shares Outstanding for LYEL at $21.3 million in Q4 2025, $19.3 million in Q3 2025, and $14.8 million in Q2 2025.